Subject Index

AA. *See* Adjuvant arthritis
Acetylcholine receptor (AChR)
  antibodies to
    lymphoid organ cells secreting, 275, 280
    after nasal administration, 274-275, 277, 278, 285
    after tolerization, 274-275
  cytokines reactive to, 275
  in EAMG induction, 273
  in EAMG-tolerized rats, 276, 278
  in EAMG treatment
    antibody responses, 261-262
    immunogenic property of, 267-268
    inhibition, 268-269
    lymphocyte responses to, 262-263
    mechanism of, 263-264
    oral tolerance, 264-266
    prevention, 260-261, 273
    specificity of, 263
    tolerogenic effects with, 268
  in MG, 258-259
  and oral tolerance, 260-269
Adjuvant arthritis (AA)
  CII oral tolerance and, 298
  prevention by CII, 297, 299
  regulation of, 425-426
Adjuvants. *See also* Complete Freund's adjuvant
  mucosal adjuvants, 64-65, 67-68
  and mucosal immunity, 76-77
Aflatoxin B_1 (AFB), 422-423
Ags. *See* Antigens
Allorecognition mechanisms, 338-339
Anergy. *See also* Clonal anergy
  CD/TCR expression and, 73-74
  induction of, 28, 74-75, 103-108
  measurement of, 163
  oral Ag and, 111-113
  as oral tolerance mechanism, 103-106, 321-323
  and peripheral tolerance maintenance, 73
  and tolerance, 105
  in vivo reversal of, 382-383
Antibodies. *See* Immunoglobulins
Antigen(s) (Ags). *See also* Oral antigen; Systemic antigen
  analogue-modulated responsiveness of, 95
  delivery of
    inhalation, 196-200, 371-372, 410-411
    inhalation *vs.* oral, 231-240, 275-285
    inhalation *vs.* parenteral, 408-409
    MES oral, 158-161
    and suppression, 16
  intestinal trafficking of, 28-34
  soluble protein Ags. *See* Cholera toxin; Diphtheria toxoid; Keyhole limpet hemocyanin; Ovalbumin; Tetanus toxoid
  and T cell anergy, 113
  uptake routes of, 6
Antigen-presenting cells (APC). *See also* Antigen processing; Intraepithelial lymphocytes
  and Ag encounter outcome, 17
  dendritic type, 5-6
  distribution of, 17
  in immune response induction, 5, 28-30
  and immunoresponsiveness, 18
  in intestinal Ag trafficking, 28-31
  in respiratory tract, 19
  tolerance/immunity role of, 72-78
  and tolerance induction, 17-19, 95-96
Antigen processing. *See also* Antigen-presenting cells
  DCs in, 47-53
  by IEC, 29-33
  in intestine, 95-96
  in Peyer's patches, 6, 47-53
  and tolerance induction, 18-19, 95-96
APC. *See* Antigen-presenting cells
Apoptosis
  following high-dose OVA, 112-113
  of peripheral lymph node cells, 131
  systemic Ag induction of, 170
  of T cells, 20
  tolerance induction and, 128-129
  of tolerized lymphocytes, 127-130
  visualization of, 113
Arthritis. *See also* Adjuvant arthritis; Collagen-induced arthritis; Rheumatoid arthritis
  adjuvant-induced, 111
  bystander suppression and, 95
  experimental arthritides. *See also* Experimental autoimmune encephalomyelitis; Experimental autoimmune uveitis
    in autoimmunity control studies, 297
    prevention/cure of, 302-303
    suppression of, 298
  oral tolerance in
    animal models of, 297-298
    suppression in, 298-301
    in therapy for, 111
  suppression of
    by collagen peptides, 301-302
    epitope spreading in, 302
    oral tolerance and, 298-301

Autoimmune diseases. *See also* Experimental autoimmune encephalomyelitis; Experimental autoimmune uveitis; Rheumatoid arthritis
bystander suppression of, 95
CTB treatment for, 191-193
IFN-β and, 149-153
immunologic toleranced and, xiii
oral tolerance therapy for, 111, 149
treatment of
in animals, xvi-xvii
in humans, xvii

Bacteria
IgA response to, 31
intracellular trafficking pattern for, 31
M cell uptake of, 31, 33
BALT. *See* Bronchus-associated lymphoid tissue
B cells
as APC, 6
B7 costimulatory molecule in, 16
clonal deletion in, 72
CT and, 76
in external secretions, 8
in FAE, 4
GALT source of, 77, 78
in lamina propria, 7
in M-cell pockets, 16, 19
migration of, 6-7
in oral tolerance, 58
regionalization of, 5-6
in T-cell activation, 75
T-cell interdependence with, 77-78
in tolerance induction, 75, 77-78
Besredka, A., 8
Bronchus-associated lymphoid tissue (BALT), 5, 7
Brünner, J.C., 3
B7 costimulatory molecule
in activated B cells, 16
APC expression of, 18
CT induction of, 76
and T cell activation, 167-168
Bystander suppression
in autoimmune disease models, xvi
of autoimmune diseases, 95
and oral tolerance, xv-xvi
TGF-β in, 115

CD11, 47
CD25, 15
CD28, 16
CD45, 12
CD54, 17
CD cells. *See under* T cells
Celiac disease
CT in, 210-214
DTH in, 202
gut immunostimulant in, 210-211, 213-214
Igs titer in, 203
intestinal antibodies in, 210
pathogenesis of, 207
CFA. *See* Complete Freund's adjuvant
Chase, M., xiii, 15
Chase-Sulzberger phenomenon, 15
Chemokines. *See also* Cytokines
gene expression regulation, 434-437
HGG effect on, 135-136
identification of, 133-134
Cholera toxin (CT)
and AFB mucosal tolerance, 422-423
antibody responses to
in celiac patients, 210-214
in Crohn's disease, 212
and B cells, 76
dose-dependent DTH responses to, 204-205
and DTH tolerance, 203-204
in immune responses, 67-68
immunogenicity mechanisms of, 76
as mucosal adjuvant, 64-65
and mucosal immunity, 76
and mucosal Th2 cell generation, 427-428
in oral tolerance, 19, 204-205
Cholera toxin B subunit (CTB)
in autoimmune disease treatment, 191-193
in systemic tolerance induction, 188-191
CIA. *See* Collagen-induced arthritis
CII. *See* Collagen II
Clonal anergy
DTH suppression and, 94
MHC class II levels and, 94
in neonatal oral tolerance, 94
and oral tolerance, 103-108, 112-113
and peripheral tolerance, 73
Clonal deletion
in B cells, 72
of $CD4^+$ cells, 112-115
and high-dose oral tolerance, 112-115
and peripheral tolerance, 73
Collagen II (CII)
arthritides suppression by, 297-302
in experimental arthritis prevention/cure, 302-304
in RA therapy, 306-314
T-cell response to, 301-302
Collagen-induced arthritis (CIA)
inhalation of CII and, 410-411
oral tolerance suppression of, 298-304
specific-Ag modification of, 297
Complete Freund's adjuvant (CFA), 74-75, 77, 78

Crohn's disease, 203, 210, 212
CsA. *See* Cyclosporine A
CT. *See* Cholera toxin
CTB. *See* Cholera toxin B subunit
CTL. *See* Cytotoxicity mediated by T lymphocytes
Cyclosporine A (CsA)
  in EAU treatment, 326, 329, 333, 336
  and oral tolerance induction, 376-377
Cytokines. *See also* Chemokines; specific cytokines
  and AChR, 275
  in EAE regulation, 116-117
  in EAMG development, 275-286
  in EAU, 315-323
  and oral tolerance, 315-323
  OVA-induced production of, 169
  production of, 103-104
  SC regulation by, 12
  suppressive, 103-104, 111. *See also* Transforming growth factor-β
    GALT secretion of, xv
  Th secretion of, 76, 104-108, 112-118
  and tolerance, 95, 104-105
Cytotoxicity mediated by T lymphocytes (CTL), 186

Dakin, R., 14
Davies, A., 8
DCs. *See* Dendritic cells
Delayed-type hypersensitivity (DTH)
  in celiac disease, 202
  to CT, 204-206
  HGG inhibition of, 135, 137, 141
  IFN-γ and, 95
  protein deprivation and, 204
  suppression of, 2, 106
    and clonal anergy, 94
    by OVA, 81, 85-86, 124
  and tolerance, 19-20
  transferable tolerogenic fragments and, 95-96
Dendritic cells (DC). *See also* Antigen-presenting cells; Peyer's patches
  in Ag processing, 47-53
  and Ag transport, 73, 77, 78
  in airway epithelium, 17
  differentiation of, 50, 52
  follicular dendritic cell, 5
  in PP, 47-48, 50-53
  and T-cell proliferation, 74-75
Dexamethasone (DEX), in EAE suppression, 414-417
Diabetes. *See also* Autoimmune diseases
  bystander suppression and, 95
  insulin peptide B protection from, 371-372
  oral tolerance therapy for, 111, 149
  suppression of
    Ag dose-dependence of, 363-367
    after intranasal insulin, 371-372
    after oral insulin administration, 362-367
  type I. *See* Insulin-dependent diabetes mellitus
Diphtheria toxoid (DT), and oral tolerance induction, 56-60
Disease-modifying antirheumatic drugs (DMARDs), 310-312
DMARDs. *See* Disease-modifying antirheumatic drugs
DRIA test, 379-380
DT. *See* Diphtheria toxoid
DTH. *See* Delayed-type hypersensitivity

EAE. *See* Experimental autoimmune encephalomyelitis
EAMG. *See* Experimental animal model of myasthenia gravis
EAU. *See* Experimental autoimmune uveitis
Ehrlich, P., 5
Epithelial transmembrane secretory component (SC)
  cytokine regulation of, 12
  and pIg transport, 9, 11-12
  and SIgA transport, 8-11
Experimental animal model of myasthenia gravis (EAMG)
  AChR prevention of, 260-269, 273-285
  cytokines in development of, 275-286
  mucosal tolerance in, 273-286
  oral tolerance in, 260-266, 273-274
Experimental autoimmune encephalomyelitis (EAE)
  CTB-MBP abrogation of, 191
  DEX effects on, 414-417
  MBP effects on
    via installation, 410-411
    via oral administration, 115, 141, 414-417
  mucosal tolerance in, 228-240
  oral tolerance in, 217-219
    chronic relapsing EAE, 221, 223-224
    IL-2 effects on, 382
    mechanisms of, 219-221
    peptide-induced specificity of, 393-394
    reversal of, 382-383
  oral tolerance therapy for, 111, 149
  suppression of, 117-118
    by IFN-β, 147-153
    by oral MBP, 115, 141, 414-417
  Th1 cytokines regulation of, 116-117
  Th2 inhibition of, 76
Experimental autoimmune uveitis (EAU), 95, 111, 149

oral tolerance in, 328-336
anergy/deletion and, 317-318, 321, 323
cytokine-dependent modulation of, 315-323
high-dose feeding *vs.* low-dose feeding, 228-229
IL-2 effect on, 318-319
IL-4/IL-10 effect on, 319-321
in mouse model of, 315-318
uveitogenic Ags and, 326-327

FAE. *See* Follicle-associated epithelium
Follicle-associated epithelium (FAE)
in antigen transport, 5-6
B cells in, 4
follicular dendritic cell (FDC), 5
in GALT, 4
lymphocyte populations of, 4
M cells in, 5, 47
Food hypersensitivity, 202. *See also* Celiac disease; Immune-mediated food sensitivity
Food intolerance. *See* Food hypersensitivity
Freund's adjuvant. *See* Complete Freund's adjuvant

GALT. *See* Gut-associated lymphoid tissue
Gowans, J., 7
Guieysse-Pellissier, A., 12
Gut-associated lymphoid tissue (GALT)
in Ag internalization, 76
and B-cell dissemination, 4-5
as B-cell source, 77, 78
components of, 75
in defense mechanism schemes, 2
FAE component of, 4-6
and memory-cell dissemination, 7
orally administered Ag and, xiv
and Peyer's patches, 3-4
and tolerance, 95-96

Hereman, J.F., 8
Human gamma globulin (HGG). *See also* Immunoglobulins
and chemokine/cytokine responses, 135-136
DTH inhibition by, 135, 137, 141
and MCP-1 production, 138
and MIP-1α production, 138
and Th1 cytokine responses, 135-136, 138, 141
and Th1 proliferation, 135-138, 141

IBD. *See* Inflammatory bowel disease
IDDM. *See* Insulin-dependent diabetes mellitus
IEC. *See* Intestinal epithelial cells
IEL. *See* Intraepithelial lymphocytes
IFN. *See* Interferons
IL. *See* Interleukins
Immune-mediated food sensitivity
celiac disease, 202-203, 207, 210-214
food intolerance, 202
IBD, 208-210
immunity to food antigens, 202-203
Immunity. *See also* Mucosal immune response; Mucosal immunity; Tolerance
adjuvants and, 76-78
induction of, 77-78
Immunization. *See* Adjuvants; Antigens; Mucosal vaccines
Immunoglobulins (Igs). *See also* Human gamma globulin; Polymeric immunoglobulins; Secretory immunoglobulins
external transfer of, 8-9
IgA. *See also* Secretory immunoglobulin A
bacterial induction of, 31
mucosal response of, 19, 55-60
protein-B binding to, 384-386
IgE
and airway immunosuppressive mechanisms, 16
in allergy prevention, 20
down-regulated response of, 19
OVA suppression of, 81-84
suppression of, 2
IgG
age-related response of, 15
in oral tolerance, 56-58
OVA suppression of, 81-86
suppression of, 2
IgM. *See also* Secretory immunoglobulin M
in external secretions, 8
oral vaccine and, 56
transport of, 8-9
SC-dependent transport of, 10-12
Immunoresponsiveness
disparity in
APC and, 18
between gut and airway, 17-19
IEL and, 17
nonimmunologic factors regulating, 28
Immunosuppressive mechanisms, 17-19. *See also* Oral tolerance; Suppression
Inflammatory bowel disease (IBD), 208-210
Inhalation tolerance. *See* Nasal tolerance
Insulin
in diabetes protection
via intranasal administration, 371-372
via oral administration, 362-366, 418-421

in IDDM prevention, 418-421
Insulin-dependent diabetes mellitus (IDDM)
autoimmune nature of, 346-347
oral antigen induction of
cytokine expression associated with, 349-351
regulatory cell lines generated by, 351-356
oral insulin and, 418-421
Interferon-β (IFN-β). *See also* Cytokines
and cytokine production, 148
EAE suppression with, 147-153
in oral tolerance induction, 145
and response to MBP, 149-150
Interferon-γ (IFN-γ). *See also* Cytokines
Ag-induced secretion of, 115, 124
antiintracellular parasite activity of, 76
and DTH response, 95
in EAMG, 275, 278, 283-286
IFN-β-induced secretion of, 151, 153
immune function regulation by, 129
OVA-induced secretion of, 104-105
production of
with oral myelin, 254-257
transgenic cells in, 169-170
with TT, 254-255
and *S. typhimurium* infection, 65
Th1 secretion of, 64
in Th2 suppression, 19, 56
Interleukins. *See also* Cytokines IL-2
in immunity against intracellular parasites, 76
Th1 secretion of, 64
IL-4
Ag-induced secretion of, 115-118
in clearance of extracellular parasites, 76
in EAE protection, 390-392
in EAMG, 275, 278, 283-286
in vivo administration of, 390-392
MBP-influenced secretion of, 116-118
and MLN T-cell response, 427-428
oral myelin-induced production of, 254-257
OVA-induced suppression of, 129
selective expression of, 349-351, 355-356
in TGF-β-producing cells induction, 390-392
in Th1 inhibition, 56
Th2 secretion of, 64
IL-5
in clearance of extracellular parasites, 76
OVA-induced suppression of, 129
Th2 secretion of, 64
IL-6
in humoral immunity, 76
and IgA synthesis, 64
response to *Salmonella* vaccine, 65-66
Th2 secretion of, 64
IL-10
Ag-induced secretion of, 115
in clearance of extracellular parasites, 76
MBP-influenced secretion of, 116-118
OVA-induced suppression of, 129
selective expression of, 349-351, 355-356
Th2 secretion of, 64
IL-13, in humoral immunity, 76
Intestinal epithelial cells (IEC). *See also* Intraepithelial lymphocytes
Ag presentation by, 29-34
Intestine, Ag trafficking in, 28-34
Intraepithelial lymphocytes (IEL). *See also* Antigen-presenting cells; B cells; T cells
and Ag uptake, 30-34
biological activity of, 12-14
development of, 36-45
glucocorticoid signaling responses of, 431-433
and immunoresponsiveness, 17
thymectomy and, 38-45

Keyhole limpet hemocyanin (KLH)
in intranasal immunization, 196-200
in oral immunization, 195-198
and oral tolerance in humans, xiii
oral tolerance to, 398-404
in peripheral T-cell response, 15
KLH. *See* Keyhole-limpet hemocyanin

β-Lactoglobulin (βLG), as tolerogen, 80-82
Lamina propria
B-cell migration to, 7
Ig-producing immunocytes in, 8, 36
Lamina propria monocytes
and accessory-receptor ligand down-regulation, 179-182
and T-cell proliferation, 182-183
Lamina propria T lymphocytes (LPL)
$CD4^+$, 5, 12
in mucosal immune system, 174-181
signaling down-regulation in, 175-177
unresponsiveness mechanisms in, 174-183
βLG. *See* β-Lactoglobulin
LPL. *See* Lamina propria T lymphocytes
Lymphocytes. *See* Intraepithelial lymphocytes; Lamina propria T lymphocytes

Macrophage inflammatory protein-1α (MIP-1α), 134-141. *See also* Chemokines

expression of, 134
HGG-inhibited production of, 138
as T-cell chemotactic factor, 139
Macrophages
in Ag transport, 73
bacterial uptake by, 33
in B-cell differentiation, 5
IFN-γ activation of, 65, 66
Major histocompatibility complex (MHC)
in gut/airway immunoresponsiveness, 17
in IEC-IEL interactions, 13
Major histocompatibility complex (MHC) class I, 72
and Ag presentation, 12
$CD8^+$ binding to, 13
expression of, 73-74
in gut epithelium, 116
gut epithelium expression of, 116
TCRγδ recognition of, 13
Major histocompatibility complex (MHC) class II
and Ag presentation, 12-14
and Ag processing, 32
$CD4^+$ Th cell stimulation by, 17
and clonal anegy, 94
DC expression of, 47, 50, 53, 74-75
enterocyte expression of, 12, 17
expression of, 74, 94
in immunity induction scheme, 77
leakage to class I pathway, 18-19
in neonatal oral tolerance, 94-95
in oral tolerance, 16-19
and superantigens, 72
TCRγδ recognition of, 13
in TT traffic, 30
Major histocompatibility complex (MHC) peptides
in allorecognition, 338-339
in oral tolerance, 340-343
MALT. *See* Mucosa-associated lymphoid tissue
MBP. *See* Myelin basic protein
M cells. *See also* Peyer's patches
absorptive abilities of, 76
in Ag transport, 5-6, 29, 47-48, 53
in FAE, 5-6
in GALT, xiv
and immune response, 19-20
insoluble Ag uptake by, 31, 34
and luminal Ag sampling, 76
microbial binding to, 29
in PPs, 17, 19
soluble Ag uptake by, 20, 33-34
MCP-1. *See* Monocyte chemotactic protein-1
Memory cells. *See* B cells
MES. *See* Multiple emulsion system
Methotrexate, 306, 310-312. *See also* Disease-modifying drugs
MG. *See* Myasthenia gravis
MIP-1α. *See* Macrophage inflammatory protein-1α
Mithridates VI-Eupator, 7-8
Monocyte chemotactic protein-1 (MCP-1). *See also* Chemokines
HGG-influenced production of, 138
identification of, 134
in oral tolerance induction, 134-141
as T-cell chemotactic factor, 139
MS. *See* Multiple sclerosis
Mucosa-associated lymphoid tissue (MALT). *See also* Bronchus-associated lymphoid tissue; Gut-associated lymphoid tissue
functions of, 185-186
Mucosal immune responses. *See also* Oral tolerance
APCs and, 5, 28-30
bacterial induction of, 65-66
to CT, 67-68
to DT, 56-60
IgA response
Ag-specific, 55
DT-specific, 58-59
γδ T cells role in, 59-60
nonimmunologic factors regulating, 28
to *Salmonella* vaccine, 66-68
Th1/Th2 cells in, 64-69
Mucosal immune system
and Ag trafficking, 28-34
defense mechanism schemes, 2
history of, 1-2
IgA response in, 55-60
inductive sites of
BALT, 5, 7
GALT, 2-7
MALT, 5-6
mucosal effector sites, 6-7
role of lymphoepithelial structures, 2-6
memory cell dissemination in, 6-7
Th1/Th2 cells in, 64-69
Mucosal immunity. *See also* Mucosal immune responses
adjuvants and, 76
CT and, 76
SIgA in, 5, 8-12, 19-20
Mucosal tolerance. *See also* Nasal tolerance; Oral tolerance
to AFB, 422-423
in EAE, 228-240
in EAMG
anti-AChR antibodies in, 274, 275, 278-280

cytokine-producing cell distribution, 275, 278-280
muscle AChR loss in, 275, 282
and muscular weakness, 274
oral *vs.* nasal administration and, 275-285
suppression of IFN-γ and, 273-274
TGF-β in induction of, 275-286
flour-dust-induced, 395-397
Mucosal vaccines. *See also* Adjuvants; Antigens
CT, 65-69, 187-192
CTB, 188-193
and CTL induction, 186
DT, 56-60
and oral tolerance, 56-60
recombinant *Salmonella* vaccine, 64-68
and SIgA expression, 186-187
TT, 64-69, 254-255
Multiple emulsion system (MES)
constituents of, 158
in immunity induction, 388-389
for oral-Ag delivery, 156-157, 388-389
in oral tolerance induction, 156-161, 388-389
Multiple sclerosis (MS). *See also* Experimental autoimmune encephalomyelitis
oral myelin tolerization in
and Ag-specific T cells, 251-252, 254, 256-257
and cytokine-secreting T-cell lines, 254-257
with MBP, 251, 254-257
with PLP, 254-257
and TGF-β secretion, 251-252, 254-257
oral tolerance study
EDSS measurement, 245-248
with MBP, 243-244
open protocol continuation, 248-249
outcome-treatment correlation, 248
oral tolerance therapy for, 111, 149, 153
Myasthenia gravis (MG). *See also* Autoimmune diseases; Experimental animal model of myasthenia gravis
AChR in, 258-259
anti-AChR antibodies and, 269
oral tolerance in, 258-259
pathology of, 258-259
Myelin basic protein (MBP)
active suppression by, 112
dose-dependent anergy induction, 228
in dose-dependent suppression, 229
in EAE suppression, 217-221, 223-226
with CTB, 191
and cytokine response, 148-149
inhalation *vs.* oral administration, 231, 233-240
oral feeding effects, 414-417
TGF-β and, 228, 238
oral tolerization to
and cytokine production, 56, 116-118, 251-252, 254-257
in EAE, 115-118
in MS, 251-257
prolonged oral administration of
DTH responses to, 358-360
immune responses to, 358-361
Th1 suppression by, 116

Nasal tolerance. *See also* Mucosal tolerance; Oral tolerance
anti-AChR antibodies and, 274-275, 280, 285
in diabetes, 371-372
after disease onset, 233-235
to EAE, 231, 233-240, 410-411
in EAMG, 273-285
via inhalation
effectiveness of, 231-240
and immunization, 196-199
with KLH, 196-200
vs. oral administration, 275-285
via installation
immune deviation during, 408-411
vs. parenteral Ag access, 408-409
Neonatal gut-origin sepsis, 405-406
Neonatal oral tolerance
induction of, 88, 98
Ag-dose effects, 91-92
Ag presentation and, 97
Ags in, 89
via gavage *vs.* breast milk, 92-93
intestinal Ag processing and, 95-97
priming persistence, 90-91
response to challenge, 93
time course of, 89-90
weaning period and, 90
regulatory mechanisms of
Ag response modulation, 95
clonal anergy in, 94
cytokine involvement, 95
MHC class II expression, 74, 94
suppressor T cells in, 94
T cells and, 58-60

Oral antigens
MES delivery of, 156-161
T-cell responses to, 166-167
TCR effects of, 163-171
Oral tolerance. *See also* Food tolerance; Neonatal oral tolerance
in AA, 298

absorbed-Ag role in, 106-108
AChR and, 260-269
active suppression and, 115-118
as Ag-driven peripheral tolerance, 103
Ags inducing, 203
and allergic reactions, 187-188
to alloantigens, 339-340
anergy and, 103-106, 321-323
in arthritis suppression, 111, 297-301
in autoimmune disease treatment, 111, 149, 187-188
autoimmunity suppression by, xvi
B cells in, 58
breaking of, 373-374
bystander suppression and, xv-xvi
$CD8^+$ in, 5, 15-16, 55-56, 122
chemokines in, 133-141
  gene expression regulation of, 434-437
in chronic relapsing EAE, 221, 223-224
in CIA suppression, 298-304
clonal anergy and, 103-108, 112-113
clonal deletion and, 112-115
to cow milk protein, 429-430
CT and, 19, 204-205
cytokine-mediated suppression and, 103-104, 111, 148-149, 315-323
in diabetes therapy, 111, 149
and DTH avoidance, 187-188
DT-specific T-cell responses in, 58-59
in EAE, 217-224, 393-394
in EAMG, 264-266
  antibody responses in, 261-262
  clinical picture in, 273-274
  lymphocyte responses, 262-263
  mechanism of, 263-264
  and prevention, 260-261
  specificity of, 263
in EAU, 228-229, 315-323, 328-336
to gliadin, 204, 206
history of, 14-15
in humans, xiii
  via intranasal immunization, 196, 198-199
  via oral immunization, 195-197
IgG in, 56-58
induction of
  Ag presentation and, 97
  CsA effects on, 376-377
  DT in, 56-60
  IFN-β in, 145
  immunization schedule for, 56-58
  intestinal Ag processing and, 95-97
  by MBP, 115-118, 230-231, 251-257
  MCP-1 in, 134-141
  MES in, 156-161, 388-389
  by oral vaccine, 56-58
  variables in, 156-157
to insulin, 346-356
interleukins and, 318-321
to KLH, 398-404
lymphocyte responses and, 262-263
in MBP TCR transgenic mice, 223, 225-226, 412-413
mechanisms of, xv, 15-20
  AChR in, 268
  anergy as, 103-106, 321, 323
  in EAE, 219-221
  MHC peptides in, 340-343
  suppressor cells in, 263-264
in MG, 258
MHC peptides and, 340-343
in MS, 111, 149, 153, 243-249
mucosal vaccines and, 56-60, 187-188
by nonpolymorphic MHC peptides, 341-343
overview of, xiii-xv
pathways of
  high-dose, 111-115
  low-dose, 115-118
peptide-induced specificity of, 393-394
and peripheral tolerance, 103, 108
to PLP, 251-257
problems and future studies in, 199-200
protein malnutrition and, 204
in RA therapy, 111, 379-380
reversal of, 382-383
SIgA response and, 55-59
suppression in, 112, 298-301, 321
TGFβ in, 19-20, 122
Th2 cell noninvolvement in, 124-131
topics included, xiv
in uveitis therapy, 111, 325-336
Ovalbumin (OVA)
and anergy, 104
and cytokine secretion, 105
DTH suppression by, 81, 85-86
Ig suppression by, 81-86
IL suppression by, 129
and T-cell priming, 130
and Th inactivation, 122-131
tolerance induction by, 104-107
as tolerogen, 80-86

Peripheral tolerance
Ag feeding and, 133
clonal anergy and, 73
clonal deletion and, 73
to exogenously administered Ags, 74-75
maintenance of, 73
oral Ag induction of, 75-77
oral tolerance and, 103, 108
Peyer, J.C., 3-4
Peyer's patches (PP). *See also* M cells
Ag processing in, 6, 47-53

DC populations in, 47-48, 50-53
discovery of, 3
distribution of, 3-4
in GALT, 3-4
immune response in, 19-20
in intestinal immune responses, 5
pIg. *See* Polymeric immunoglobulins
PLP. *See* Proteolipid protein
Polymeric immunoglobulins (pIg)
SC-dependent transport of, 9-12
transport model for, 9
PP. *See* Peyer's patches
Protein B, 384-386
Proteolipid protein (PLP)
cytokine production with, 255
induction of EAE by, 115, 117-118
oral tolerization to, with MS, 251-252, 254-257
TGFβ response to, 254

Rheumatoid arthritis (RA). *See also* Autoimmune diseases
CII therapy for, 306-309
future of, 312-314
palliation, 311-312
suppression, 309-310
trials, 310-311
collagen-feeding suppression of, 309-312
diet and, 379-380
food tolerance and, 379-380
methotrexate treatment, 306
oral tolerance therapy for, 111, 379-380
pathogenesis of, 306-307
problems with, 306

Salmonella vaccine, 66-68
SC. *See* Epithelial transmembrane secretory component
Secretory immune system, 8-12
Secretory immunoglobulin A (SIgA)
CT induction of, 65
in exocrine secretions, 8
in mucosal immunity, 5, 8-12, 19-20
mucosal response of, 55-60
production of, 9-11
SC transport of, 8-11
Secretory immunoglobulin M (SIgM), 9, 11-12
Secretory immunoglobulins
epithelial transport of, 10
in exocrine secretions, 8
mucosal response
of SIgA, 55-60
of Th cells, 64-69
mucosal vaccines and, 186-187
in neonatal gut-origin sepsis protection, 405-406
and oral tolerance, 55-58
physicochemical properties of, 8
SC transport of, 5, 9-12
T-cell regulation of, 58-60
transport models for, 9-11
South, M.A., 8-9
Sulzberger, M.B., 15
Suppression. *See also* Bystander suppression; Oral tolerance
of arthritis, 298-302
and autoimmune disease modulation, 20
$CD4^+$ cells and, 2, 14, 116, 128-131
$CD8^+$ cells and, 116, 124-131
of cytokine production, 124, 126
cytokines in, 103-104, 111
of diabetes, 362-367, 371-372
of DTH
by absorbed Ag, 2, 106
and clonal anergy, 94
by OVA, 81, 85-86, 124
of EAE, 115, 117-118, 141, 147-153
of EAU, 316-318, 321
of IgE, 2, 81-84
and IgE-mediated allergy prevention, 20
of IgG, 2, 81-86, 107, 124-125
intranasal KLH in, 15
and low-dose oral tolerance, 115-118
MBP-dependent, 115
in oral tolerance, 112, 321
and T-cell differentiation, 163
Systemic antigens
apoptosis induction by, 170
splenic T-cell responses to, 168
and T-cell trafficking, 166-167

T cell(s). *See also* Intraepithelial lymphocytes
activation of
B cells in, 16, 75
B7-mediated costimulation and, 167-168
Ag-induced differentiation of, 168-170
Ag-specific, 72-78
anergy in. *See* Anergy; Clonal anergy
apoptosis of. *See* Apoptosis
B-cell interdependence with, 77-78
CD1
Ag-presenting function of, 12-13, 288-294
CD8 association of, 31-32
in CD8 T-cell stimulation, 16
mCD1-binding peptides, 289-291
molecular biology of, 288-289
trafficking of mCD1, 291-293
CD3, 12, 50, 52
$CD4^+$
in B-cell differentiation, 5

cytokine profiles of, 116-117
DTH mediation by, 2
EAE inhibition by, 76
in IgA response regulation, 55-60
MHC stimulation of, 18
and OVA-induced tolerance, 122-131
suppression of, 14, 128-131
in thymectomized mice, 38-45
CD8+
activation of, 30-32
APC interaction with, 34
cytolytic activity of, 12
epithelial binding of, 7
IFN-γ production by, 19
in IgA response regulation, 55-60
MHC stimulation of, 18
in oral tolerance, 5, 15-16
suppression of, 124-131
TGF-β production by, 116
in thymectomized mice, 38-45
CTL, 186
cytokine secretion by, 76, 103-108, 112-118
distribution in villi, 12
γδ cells
in mucosal IgA response regulation, 55-60
and mucosal surface surveillance, 13-14
migration of, 7
in mucosal IgA response, 55-60
oral Ag-induced responses of, 166-167
and oral tolerance, 58-59
in SIgA-response regulation, 55-60
systemic, 168-170
Th. *See also* CD4+ cells; CD8+ cells
anergy induction in, 111-112
cytokine secretion by, 76
OVA inactivation of, 122-131
in SIgA responses, 64-69
Th1
anergy induction in, 103-108
cytokines produced by. *See* Interferon-γ; Interleukins; Tumor necrosis factor-β
down-regulation of, 56
in EAE regulation, 116-117
HGG-influenced cytokine response of, 135-136, 138, 141
HGG-influence proliferation of, 135-138, 141
in mucosal IgA responses, 64-68
tolerance, 112-113
transgenic T-cell development to, 163-164
Th2
Ag-induced cytokine secretion by, 115
CT-mediated generation of, 427-428
cytokines produced by. *See* Interleukins; Transforming growth factor-β
down-regulation of, 56
EAE inhibition by, 76
low-dose Ag activation of, 112
in mucosal IgA responses, 64-69
and tolerance, 112
transgenic T-cell development to, 163-164
thymic development of, 36-45
in tolerance study, 73-78
Ts, 94, 111
T-cell receptor (TCR)
αβ (TCRαβ)
IEL expression of, 36
thymus production of, 40-45
and Ag-specific-T-cell monitoring, 72-78
and anergy, 73-74
expression of, 73-74
γδ (TCRγδ)
IEL expression of, 12-14, 36, 45
thymus production of, 38-41
signaling in
down-regulation of, 175-177
mucosal environment and, 177-179
regulatory influences on, 177-179
transgenic system, 163-165
TCR. *See* T-cell receptor
Tetanus toxoid (TT), 64-69. *See also* *Salmonella* vaccine
cellular uptake of, 29-30
cytokine production with, 254-255
TGF-β. *See* Transforming growth factor-β
Thymus, in IEL development, 36, 38-45
Thyroiditis. *See* Autoimmune diseases
Tolerance. *See also* Immunity; Oral tolerance; Peripheral tolerance; Tolerogens
anergy and, 105
and apoptosis, 128-129
to arthritogenic T-cell epitope, 425-426
CTB and, 188-189
and cytokines, 95, 104-105
DTH and, 19-20
to exogenously administered Ags, 74-75
in extrathymic Ag expression, 73-74
food tolerance, 379-380
GALT and, 95-96
induction of
APC role in, 73-78
B-cell role in, 75, 77-78
in humans, 194-200
oral Ag administration and, 75-76
induction via installation of, 408-411
maintenance of, 73
RA and, 379-380
systemic peripheral

induction of, 75-76
models of, 74-75
Tolerogens
administration of, 80-86
and Ag-specific T-cell proliferation, 75
protein-Ig conjugates, 81-82
Tomasi, T.B., 8
Transforming growth factor-β (TGF-β). *See also* Cytokines
antigen activation of, 112
$CD4^+/CD8^+$ secretion of, xv, 56, 76, 116
expression of
Ag-induced, 115
insulin feeding and, 349-351, 353
with oral myelin, 254-257
OVA-induced, 131
immune function regulation by, 129
MBP-influenced secretion of, 115-118, 254-257
in oral tolerance, 19-20, 122
T-cell lines secreting, 251-257
Th1 secretion of, 64
in tolerance, 95
Transplantaton tolerance, 368-369
TT. *See* Tetanus toxoid
Tumor necrosis factor-β (TNF-β)
in immunity against intracellular parasites, 76
Th1 secretion of, 64, 76

Uveitis, 325-327. *See also* Autoimmune diseases; Experimental autoimmune uveitis
oral tolerance therapy for, 111

Vaccines. *See* Antigens; Mucosal vaccines

Waldeyer's ring, 5, 7
Weber, E.H., 12
Wells, H.G., xiii, 15

Index of Contributors

Adams, R. N., 258-272
Akerblom, H. K., 429-430
Akselband, Y., 145-155, 358-361
Al-Sabbagh, A., 145-155
Anderton, S. M., 425-426
Autschbach, F., 174-184

Bansal, S., 297-305
Barrett, T. A., 163-173
Battisto, J. R., 434-437
Bene, M. C., 395-397
Bergerot, I., 362-367
Bhardwaj, V., 408-411
Bitter-Suermann, H., 368-370
Blake, M. S., 384-387
Blogg, N. S., 346-357
Bluethmann, H., 64-71
Borel, H., 80-87
Borel, Y., 80-87
Brandtzaeg, P., 1-27
Braunstein, J., 174-184
Batuman, O., 414-417

Carpenter, C. B., 338-345
Carr, R. I., 368-370
Caspi, R. R., 315-324, 325-337
Castaño, A. R., 288-296
Chan, C. C., 315-324
Chatfield, S. N., 64-71
Chen, Y. H., 111-121, 145-155, 390-392
Cook, S. L., 243-250
Cox, K. L., 217-227, 382-383, 393-394, 412-413
Czerkinsky, C., 185-193

Dahlgren, U., 80-87
Dalhman-Höglund, A., 80-87
Daniel, D., 371-372
de Smet, M. D., 325-337
Dearborn, S. M., 145-155
Dertzbaugh, M. T., 156-162
Drachman, D. B., 258-272

Elson, C. O., 156-162, 194-201

Fabien, N., 362-367
Fasani, G., 379-381
Faure, G. C., 395-397
Ferguson, A. E., 202-216
Flanagan, M., 373-375
Friedman, A., 103-110
Fritsche, R., 80-87
Fujihashi, K., 55-63, 64-71
Fukaura, H., 251-257
Fukushima, A., 376-378

Garside, P., 122-132
Gasic, G., 431-433
Gery, I., 325-337, 376-378
Gianfranceschi, P., 379-381
Gienapp, I. E., 217-227, 382-383, 393-394, 412-413
Gillett, H., 202-216
Goldschmidt, T. J., 408-411
Golling, M., 174-184
Gonnella, P. A., 145-155, 358-361
Goverman, J., 412-413
Greiner, D. L., 418-421
Grundy, M. A., 384-387

Hafler, D. A., 243-250, 251-257, 398-404
Hancock, W. W., 338-345, 346-357
Hanson, L. A., 80-87
Harper, N., 297-305
Hearn, T. L., 388-389
Hiroi, T., 55-63
Ho, L., 408-411
Hoffer, T. L., 358-361
Hohol, M. J., 243-250
Holcombe, H. R., 288-296
Holmgren, J., 185-193
Hood, L., 412-413
Hunter, R. L., 156-162, 388-389
Hurst, S. D., 163-173
Husby, S., 194-201
Huse, W. E., 288-296

Inobe, J. I., 390-392

Jackson, R. J., 64-71, 405-407
Jain, S., 373-375
Javed, N. H., 217-227, 382-383, 393-394
Jenkins, M. K., 72-79
Johnson, D. D., 405-407

Karpus, W. J., 133-144
Kaste, J., 429-430
Kelsall, B. L., 47-54
Kent, S. C., 251-257
Keren, D. F., 422-424
Kewin, P. J., 122-132
Khoruts, A., 72-79
Khoury, S. J., 243-250, 251-257, 338-345
Kiyono, H., 55-63, 64-71
Klemetti, P., 429-430
Kolopp-Sarda, M. N., 395-397
Kozhich, A. T., 325-337

Kronenberg, M., 288-296
Kuis, W., 425-426

Lebens, M., 185-193
Ledingham, D., 368-370
Lee, H. O., 163-173
Lee, T. D. G., 368-370
Lefrançois, L., 36-46
Li, B. L., 185-193
Lindblad, M., 185-193
Link, H., 273-287
Link, J., 273-287
Lukacs, N. W., 133-144

Ma, C. G., 273-287
Major, J. A., 434-437
Maloney, C., 368-370
Marinaro, M., 64-71
Maron, R., 346-357
Massin, N., 395-397
Matsui, M., 398-404
Maxson, R. T., 405-407
Mayer, A., 362-367
Mayer, L. F., xiii-xviii, 28-35
McAlister, V., 368-370
McDonald, R. A., 422-424
McGhee, J. R., 55-63, 64-71
McI Mowat, A., 122-132
McIntosh, K. R., 258-272
Melo, M. E. F., 408-411
Mestecky, J., 194-201
Metzler, B., 228-242
Meuer, S. C., 174-184
Meyer, A., 217-227, 412-413
Michael, J. G., 373-375
Miller, A., 408-411
Miller, B., 422-424
Miller, J. E., 288-296
Miller-Rivero, N. E., 315-324
Mokhtarian, F., 414-417
Moldoveanu, Z., 194-201
Morawetz, R., 315-324
Mordes, J. P., 418-421
Morse III, H. C., 315-324
Murray, K., 384-387

Nelson, P. A., 145-155, 358-361, 418-421
Nussenblatt, R. B., 315-324, 325-337, 376-378

O'Mahony, S., 202-216
Okahashi, N., 64-71
Okumura, S., 258-272
Oliver, A. R., 422-424
Olsen, M., 388-389
Olsson, T., 273-287
Orav, E. J., 243-250

Peterson, P. A., 288-296
Pietrusewicz, M. J., 251-257
Polanski, M., 346-357
Prakken, B. J., 425-426
Puddington, L., 36-46

Qiao, L., 174-184

Rask, C., 185-193
Rizzo, L. V., 315-324
Roipko, D., 418-421
Rosenberg, J. G., 163-173
Rossini, A. A., 418-421

Samson, M., 368-370
Saukkonen, T., 429-430
Savilahti, E., 429-430
Sayegh, M. H., 338-345
Schaffeler, M., 427-428
Schirf, B., 418-421
Schürmann, G., 174-184
Sercarz, E., 408-411
Shi, Y., 414-417
Shirazian, T., 414-417
Silbart, L. K., 422-424
Small, G., 28-35
Smith, M. P., 163-173
Smith, S. D., 405-407
Snider, D. P., 427-428
So, L. P., 28-35
Speciani, A. F., 379-381
Staines, N. A., 297-305
Steel, M., 122-132
Stiff, L. R., 315-324
Strobel, S., 88-102
Strober, W., 47-54
Sun, J. B., 185-193

Tangri, S., 288-296
Teitell, M., 288-296
Thaggard, G., 156-162
Thivolet, C., 362-367
Thompson, H. S. G., 297-305
Tian, Z. J., 145-155
Tomasi, M., 156-162
Trentham, D. E., 306-314

Vaarala, O., 429-430
van den Wall Bake, A. W. L., 194-201
van der Zee, R., 425-426
van Eden, W., 425-426
Van Houten, N., 431-433
van Kooten, P., 425-426
Vancott, J. L., 64-71
Vistica, B., 325-337

Waldo, F. B., 194-201
Wang, Z. Y., 273-287
Ward, F. J., 297-305
Weaver, C., 156-162
Wegmann, D. R., 371-372
Weiner, H. L., xiii-xviii, 111-121, 145-155, 243-250, 251-257, 325-337, 338-345, 346-357, 358-361, 390-392, 398-404, 418-421
Whitacre, C. C., 217-227, 382-383, 393-394, 412-413
Whitcup, S. M., 325-337, 376-378
Wiggert, B., 315-324
Worthey, E. A., 122-132
Wraith, D. C., 228-242

Xiao, B. G., 273-287

Yamamoto, M., 55-63, 64-71
Yio, X. Y., 28-35
Yuan, Y. S., 434-437

Zamvil, S. S., 145-155
Zhang, G. X., 273-287
Zhou, J., 368-370